Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr

Movement Disorders

Volumn 30, Issue 1, 2015, Pages 19-36

  Lees, Andrew J ^a   Tolosa, Eduardo ^b   Olanow, C Warren ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BARCELONA   (Spain)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; L dopa; Neuromelanin; Reserpine; Substantial nigra

Indexed keywords

AJMALINE; DOPAMINE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NEUROMELANIN; NEUROTRANSMITTER; NORADRENALIN; RESERPINE; SERPENTINE; YOHIMBINE; ANTIPARKINSON AGENT;

BLOOD PRESSURE; BRADYKINESIA; BRAIN; CORPUS STRIATUM; DEPLETION; DISEASE SEVERITY; DOPAMINE BRAIN LEVEL; DRUG MEGADOSE; DYSKINESIA; FLUORESCENCE; HEMATOLOGIC DISEASE; HUMAN; IMMOBILITY; LABORATORY TEST; LITERATURE; LOW DRUG DOSE; MEDICAL EDUCATION; MEDICAL RESEARCH; MEDICAL SCHOOL; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROLOGIST; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PLANT ROOT; PRECURSOR; PRIORITY JOURNAL; RAUWOLFIA; REVIEW; RIGIDITY; SUBSTANTIA NIGRA; TREMOR; AWARDS AND PRIZES; HISTORY; MALE; NEUROLOGY; PHARMACOLOGY;

ANTIPARKINSON AGENTS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LEVODOPA; MALE; NEUROLOGY; NOBEL PRIZE; PARKINSON DISEASE; PHARMACOLOGY;

EID: 84920921975     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26120     Document Type: Review

References (96)

1. Siddiqui S, Haider SI, Ahmad SS, Siddiqui BS. Alkaloids of Rauwolfia serpentina benth. J Indian Chem Soc 1939;16:421-422.
2. Vakil RJ. A clinical trial of Rauwolfia serpentina in essential hypertension. Br Heart J 1949;11:350-355.
3. Kline NS. Use of Rauwolfia serpentina Benth. in neuropsychiatric conditions. Ann N Y Acad Sci 1954;59:107-132.
4. Bleuler M, Stoll WA. Clinical use of reserpine in psychiatry: comparison with chlorpromazine. Ann N Y Acad Sci 1955;61:167-173.
5. Brodie BB, Pletscher A, Shore PA. Evidence that serotonin has a role in brain function. Science 1955;122:968.
6. Carlsson A, Shore PA, Brodie BB. Release of serotonin from blood platelets by reserpine in vitro. J Pharmacol Exp Ther 1957;120:334-339.
7. Hillarp NA, Hokfelt B. Histochemical demonstration of noradrenaline and adrenaline in the adrenal medulla. J Histochem Cytochem 1955;3:1-5.
8. Carlsson A, Hillarp NA. Release of adenosine triphosphate along with adrenaline and noradrenaline following stimulation of the adrenal medulla. Acta Physiol Scand 1956;37:235-239.
9. Bertler A, Rosengren E. Occurrence and distribution of dopamine in brain and other tissues. Experientia 1959;15:10-11.
10. Carlsson A, Lindqvist M, Magnusson T. 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957;180:1200.
11. Carlsson A, Lindqvist M, Magnusson T, Waldeck B. On the presence of 3-hydroxytyramine in brain. Science 1958;127:471.
12. Carlsson A, Hillarp NA. On the state of the catechol amines of the adrenal medullary granules. Acta Physiol Scand 1958;44:163-169.
13. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 1959;11:490-493.
14. Carlsson A, Falck B, Hillarp NA, Thieme G, Torp A. A new histochemical method for visualization of tissue catechol amines. Med Exp Int J Exp Med 1961;4:123-125.
15. Carlsson A, Falck B, Hillarp NA. Cellular localization of brain monoamines. Acta Physiol Scand Suppl 1962;56:1-28.
16. McLellan H. Synaptic Transmission. Philadelphia: W.B. Saunders, 1963.
17. Carlsson A. Treatment of Parkinson's with L-DOPA: the early discovery phase, and a comment on current problems. J Neural Transm 2002;109:777-787.
18. Blaschko H. Metabolism and storage of biogenic amines. Experientia 1957;13:9-13.
19. Montagu KA. Catechol compounds in rat tissues and in brains of different animals. Nature 1957;180:244-245.
20. Sano I, Gamo T, Kakimoto Y, Taniguchi K, Takesada M, Nishinuma K. Distribution of catechol compounds in human brain. Biochim Biophys Acta 1959;32:586-587.
21. Hornykiewicz O. Dopamine miracle: from brain homogenate to dopamine replacement. Mov Disord 2002;17:501-508.
22. Bertler A, Carlsson A, Rosengren E. A method for the fluorimetric determination of adrenaline and noradrenaline in tissues. Acta Physiol Scand. 1958;44:273-292.
23. Ehringer H, Hornykiewicz O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr 1960;38:1236-1239.
24. Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Parkinsonism Relat Disord. 1998;4:53-57.
25. Hornykiewicz O. [The topical localization and content of noradrenalin and dopamine (3-hydroxytyramine) in the substantia nigra of normal persons and patients with Parkinson's disease]. Wien Klin Wochenschr 1963;75:309-312.
26. Hornykiewicz O. [Dopamine (3-hydroxytyramine) in the central nervous system and its relation to the Parkinson syndrome in man]. Deutsche Med Wochenschr 1962;87:1807-1810.
27. Birkmayer W, Hornykiewicz O. [The L-3, 4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia.]. Wien Klin Wochenschr 1961;73:787-788.
28. Degkwitz R. [Experiences with 2 personal trials with iproniazid]. Psychiatr Neurol (Basel) 1960;140:106.
29. Degkwitz R, Frowein R, Kulenkampff C, Mohs U. [On the effects of L-dopa in man and their modification by reserpine, chlorpromazine, iproniazid and vitamin B6]. Klin Wochenschr 1960;38:120-123.
30. Barbeau A, Murphy GF, Sourkes TL. Excretion of dopamine in diseases of basal ganglia. Science 1961;133:1706-1707.
31. Costa E, Côté LJ, Yahr MD, eds. Biochemistry and Pharmacology of the Basal Ganglia. Proceedings of the Second International Symposium Sponsored by the Parkinson's Disease Information and Research Center, College of Physicians and Surgeons, Columbia University. Hewlett, NY: Raven Press, 1966.
32. Pifl C, Rajput A, Reither H, et al. Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum. J Neurosci 2014;34:8210-8218.
33. Hornykiewicz O. Autobiography: Oxford, UK: Elsevier, 2004.
34. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
35. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism: chronic treatment with L-dopa. N Engl J Med 1969;280:337-345.
36. Guggenheim M. Dioxyphenylalanin, eine neue Aminosäure aus Vicia faba. Zschr Physiol Chem 1913;88:276-284.
37. US Department of Health, Education, and Welfare. Parkinson's disease: present status and research trends. Bethesda, MD: Public Health Service, National Institutes of Health, National Institute of Neurological Diseases and Blindness, 2014: 1966.
38. Cotzias GC, Dole VP. Metabolism of amines. II. Mitochondrial localization of monoamine oxidase. Proc Soc Exp Biol Med. 1951;78:157-160.
39. Mena I, Marin O, Fuenzalida S, Cotzias GC. Chronic manganese poisoning: clinical picture and manganese turnover. Neurology 1967;17:128-136.
40. Cotzias GC, Borg DC. Phenothiazines and manganese. Res Publ Assoc Res Nerv Ment Dis 1962;40:337-357.
41. Patten BM, Sakamoto A, Vanwoert MH, Papavasiliou PS, Cotzias GC. Tremorine-induced tremor versus extrapyramidal disease. Nature 1964;201:929-930.
42. Cotzias GC, Papavasiliou PS, Miller ST. Manganese in Melanin. Nature 1964;201:1228-1229.
43. Cotzias GC. Manganese, melanins and the extrapyramidal system. J Neurosurg 1966;24(Suppl):170-180.
44. Cotzias GC. Manganese, and degenerations of the Brain. The Harvey Lectures, series 68. San Diego, CA: Academic Press, 1974.
45. Cotzias GC. Metabolic modification of some neurologic disorders. JAMA 1969;210:1255-1262.
46. Cotzias GC, Papavasiliou PS, Ginos JZ, Tolosa E. Treatment of Parkinson's disease and allied conditions. In: Tower DB, ed. The Clinical Neurosciences. New York: Raven Press; 1975:323-329.
47. Bartholini G, Burkard WP, Pletscher A. Increase of cerebral catecholamines caused by 3, 4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature 1967;215:852-853.
48. Birkmayer W, Mentasti M. [Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes)]. Arch Psychiatr Nervenkr 1967;210:29-35.
49. Siegfried J. Traitement du Parkinsonisme avec la L-dopa associée à un inhibiteur de la décarboxylase. Méd et Hyg 1969;27:543-545.
50. Tissot R, Gaillard JM, Guggisberg M, Gauthier G, de Ajuriaguerra J. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)]. Presse Med. 1969;77:619-622.
51. Cotzias GC, Papavasiliou PS. Blocking the negative effects of pyridoxine on patients receiving levodopa. JAMA 1971;215:1504-1505.
52. Papavasiliou PS, Cotzias GC, Duby SE, Steck AJ, Fehling C, Bell MA. Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor. N Engl J Med 1972;286:8-14.
53. Tang LC, Cotzias GC. L-3, 4-dihydroxyphenylalanine-induced hypersensitivity simulating features of denervation. Proc Natl Acad Sci U S A. 1977;74:2126-2129.
54. Nadjar A, Gerfen CR, Bezard E. Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? Prog Neurobiol 2009;87:1-9.
55. Mena I, Cotzias GC. Protein intake and treatment of Parkinson's disease with levodopa. N Engl J Med 1975;292:181-184.
56. Mena I, Court J, Fuenzalida S, Papavasiliou PS, Cotzias GC. Modification of chronic manganese poisoning. Treatment with L-dopa or 5-OH tryptophane. N Engl J Med 1970;282:5-10.
57. Cotzias GC, Papavasiliou PS, Fehling C, Kaufman B, Mena I. Similarities between neurologic effects of L-dopa and of apomorphine. N Engl J Med 1970;282:31-33.
58. Duby SE, Cotzias GC, Papavasiliou PS, Lawrence WH. Injected apomorphine and orally administered levodopa in Parkinsonism. Arch Neurol 1972;27:474-480.
59. Tolosa ES, Sparber SB. Apomorphine in Huntington's chorea: clinical observations and theoretical considerations. Life Sci 1974;15:1371-1380.
60. Gilbert DL, Dure L, Sethuraman G, Raab D, Lane J, Sallee FR. Tic reduction with pergolide in a randomized controlled trial in children. Neurology 2003;60:606-611.
61. Cotzias GC, Papavasiliou PS, Tolosa E, Bell-Midura MA, Ginos JZ. Aporphines in Parkinson's disease. Trans Am Neurol Assoc 1975;100:178-181.
62. Cotzias GC, Papavasiliou PS, Tolosa ES, Mendez JS, Bell-Midura M. Treatment of Parkinson's disease with aporphines: possible role of growth hormone. N Engl J Med 1976;294:567-572.
63. Ginos JZ, Cotzias GC, Tolosa E, Tang LC, LoMonte A. Cholinergic effects of molecular segments of apomorphine and dopaminergic effects of N, N-dialkylated dopamines. J Med Chem 1975;18:1194-1200.
64. Corrodi H, Fuxe K, Ungerstedt U. Evidence for a new type of dopamine receptor stimulating agent. J Pharm Pharmacol 1971;23:989-991.
65. Calne DB, Teychenne PF, Claveria LE, Eastman R, Greenacre JK, Petrie A. Bromocriptine in parkinsonism. Br Med J 1974;4:442-444.
66. Papavasiliou PS, Cotzias GC, Lawrence WH. Levodopa and dopamine in cerebrospinal fluid. Neurology 1973;23:756-759.
67. Cotzias GC, Miller ST, Tang LC, Papavasiliou PS. Levodopa, fertility, and longevity. Science 1977;196:549-551.
68. Cotzias GC, Tang LC. An adenylate cyclase of brain reflects propensity for breast cancer in mice. Science 1977;197:1094-1096.
69. Kurlan R. "Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease. Neurology 2005;64:923-924.
70. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508.
71. PD MED Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 2014; in press.
72. Salat D, Tolosa E. Levodopa . In: Pahwa R, Lyons KE, eds. Handbook of Parkinson's Disease. New York, NY: CRC Press; 2013:389-413.
73. Dole VP. George Constantin Cotzias-June 16, 1918-June 13, 1977. Biogr Mem Natl Acad Sci 1995;68:63-82.
74. In Memory of George Cotzias 1918-1977. Memorial Sloan-Kettering Cancer Center. A compilation of the testimonies read at a memorial service held at Memorial Sloan-Kettering Cancer Center on December 14, 1977.
75. Cooper IS. The Vital Probe: My Life as a Brain Surgeon. New York, NY: W.W. Norton & Company; 1981.
76. Thomas L. George C. Cotzias 1918-1977. Trans Assoc Am Physicians 1978;91:23-24.
77. Tang LC. A personal and scientific biography of Dr. George C. Cotzias. Neurotoxicology 1984;5:5-12.
78. Tolosa E. Levodopa arrives in New York. In: Poewe W, Lees A, eds. 20 Years of Madopar: New Avenues. Basel: Editiones Roche; 1994:19-42.
79. Birkmayer W, Birkmayer GJ. The L-dopa story. In: Calne DB, ed. Parkinsonism and Aging. New York, NY: Raven Press; 1989:1-7.
80. Kapp W. The history of drugs for the treatment of Parkinson's disease. J Neural Transm Suppl 1992;38:1-6.
81. Patten BM. A personal tribute to Dr. George C. Cotzias, clinician and scientist. Perspect Biol Med 1983;27:156-161.
82. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
83. th International Neurological Congress, Rome: Societa Grafica Romana, 1961;2:925-927.
84. Friedhoff AJ, Hekimian L, Alpert M, Tobach E. Dihydorxyphenylalanine in extrapyramidal disease. JAMA 1963;184:285-290.
85. Gerstenbrand F, Pateisky K, Prosenz P. Ehrfahrungen mit L-dopa in der therapie der parkinsonismus. Psychiatr Neurol 1963;146:246-261.
86. Umbach W, Baumann D. Die wirksamkeit von L-dopa bei Parkinson-patienten mit und ohne stereotaktischen himeingriff. Arch Psychiat Zeitxh Neurol 1964;205:281-292.
87. Bruno A, Bruno SC. Effetti della L-3, 4 diidrossifenilalanina (L-Dopa) nei pazienti parkinsoniani. Riv Sper Freniat 1966;90:39-50.
88. Birkmayer W, Hornykiewicz O. Weitere experimentelle untersuchungen uber L-DOPA bein Parkinson-syndrom und reserpine-parkinsonismus. Arch Psychiat Zeitsch Neurol 1964;206:367-381.
89. Rinaldi F, Margherita G, Divitus E. Effetti della soministrazione di DOPA a pazianti parkinsoniani pretrattati con inhibitore delle monoaminossidasi. Ann Fren Scienze Affini 1965;78:105-113.
90. Greer M, Williams CM. Dopamine metabolism in Parkinson's Disease. Neurology 1963;13:73-76.
91. McGeer PL Zeldowicz LR. Administration of dihydroxyphenylanine to parkinsonian patients. Can Med J Assoc 1964;90:463-466.
92. Fehling C. Treatment of Parkinson's syndrome with L-DOPA: a double blind study. Acta Neurol Scand 1966;42:367-372.
93. Hornykiewicz O. Metabolism of brain dopamine in human parkinsonism: neurochemical and clinical aspects. In Costa E, Côté LJ, Yahr MD, eds. Biochemistry and Pharmacology of the Basal Ganglia. Hewlett, NY: Raven Press, 1966:171-185.
94. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol 1969;21:343-354.
95. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
96. Alfred Lord Tennyson. The Two Voices. 1833.